Breaking Into Asia: How UK Life Sciences Companies Are Finding Their Next Growth Market

The latest episode of the Cambridge Tech Podcast features a fascinating panel discussion on international trade recorded live at this year’s Cambridge Wide Open Week.Steven Lynch, Director of International Trade at the British Chambers of Commerce (BCC), opens with a sobering statistic: whilst only 10% of British businesses export, the BCC's network achieves a remarkable 45%. This disparity represents a significant untapped opportunity. As Lynch points out, "If we increased UK exports by 2%, we could improve UK GDP by 0.6%."The problem isn't a lack of innovation or ambition; it's a delivery gap. UK founders and scientists often lack the business expertise and market clarity needed to confidently enter international markets. This is where the new trade accelerator comes in.Rather than offering generic webinars about exporting, the BCC has created something fundamentally different: an end-to-end, process-driven accelerator specifically targeting life sciences companies interested in Singapore.Singapore might not be the obvious first choice for UK startups - the US typically dominates - but it's positioned as a strategic gateway to Southeast Asia. With a population of 6 million, Singapore punches well above its weight as a hub for healthcare innovation and life sciences.Jay Sadanandan, a Singapore life sciences expert, highlights the market's unique advantages:The Health Sciences Authority recently launched a close collaboration with the UK's MHRA, enabling regulatory expediency for innovative technologiesAccess to world-class clinical research infrastructure and patient populationsSingapore's ambitious government vision to solve prevention through treatment across healthcareThe 10 selected companies span pre-seed to Series C stages and focus on areas where UK strength aligns with Singapore opportunity: genomics, molecular diagnostics, advanced therapeutics, and enabling technologies like biologic stabilisation. Importantly, companies aren't required to relocate or abandon UK operations. Instead, they use Singapore as a commercial testbed, a lower-risk environment to validate their business model before scaling across Asia Pacific, the US, or beyond.What's Next?The pilot launches in September 2026, but the ambitions extend far beyond Singapore. Lynch reveals plans to scale to Hong Kong, the Gulf, and other strategic markets. The ultimate goal? Moving from 15 businesses entering one market annually to 15 businesses entering different markets each month.For UK startup founders and investors watching the export opportunity, this episode offers genuine insight into how the next generation of British life sciences companies might achieve global scale, and why Singapore might be the launchpad you haven't considered yet.Listen to the full episode on the Cambridge Tech Podcast to hear the complete discussion, including audience Q&A and practical advice for companies considering international expansion.Headline sponsor Holden Polestar Produced by Cambridge TV #CamTechPod Hosted on Acast. See acast.com/privacy for more information.